Abstract
Background and Objective
In the last decade, a number of genes have been reported to be recurrently associated with myeloid malignancies. While some mutations are easily detectable by conventional molecular genetics methods, other mutations are more difficult to screen because of lower frequency and being scattered along large genomic ranges. However, newly developed approaches for next-generation sequencing provide an affordable solution for targeted multiplex resequencing of up to several hundreds of amplicons. Here, we aimed to develop and validate a novel custom panel for targeted resequencing of myeloid malignancy samples using the Ion PGM™ System (Ion Torrent, Paisley, UK).
Methods
We designed a pool of 424 primers for the amplification of 212 amplicons covering 99.46 % of the exonic regions of nine human genes as follows: ASXL1, EZH2, CALR, RUNX1, SETBP1, SF3B1, SRSF2, TET2, and U2AF1. Initial testing of the panel performance was performed on an Ion PGM™ machine using PGM™ 316 v2 chips on 16 DNA samples from patients with myeloid malignancies. Sequence alignment, variant calling, and annotation were performed using Ion Reporter software.
Results
We identified a total of 14 nonsynonymous somatic coding variants in seven samples affecting six of the genes in the panel (ASXL1, CALR, RUNX1, SRSF2, TET2, and U2AF1). Notably, three of the identified mutations were not present in the Cosmic v.67 release.
Conclusion
This proof-of-concept study confirms the feasibility of Ion Torrent systems for resequencing of clinically relevant mutations in myeloid malignancies. It can be particularly useful in cases without the most frequent clonal markers.
References
Murati A, Brecqueville M, Devillier R, Mozziconacci MJ, Gelsi-Boyer V, Birnbaum D. Myeloid malignancies: mutations, models and management. BMC Cancer. 2012;12:304. doi:10.1186/1471-2407-12-304.
Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–89. doi:10.1056/NEJMoa1112304.
Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496–506. doi:10.1056/NEJMoa1013343.
Loman NJ, Misra RV, Dallman TJ, Constantinidou C, Gharbia SE, Wain J, et al. Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol. 2012;30(5):434–9. doi:10.1038/nbt.2198.
Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR, et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics. 2012;13:341. doi:10.1186/1471-2164-13-341.
Luthra R, Patel KP, Reddy NG, Haghshenas V, Routbort MJ, Harmon MA, et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014;99(3):465–73. doi:10.3324/haematol.2013.093765.
Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Fu B, Tang G, et al. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res. 2015;39(3):348–54. doi:10.1016/j.leukres.2014.12.006.
Conte N, Varela I, Grove C, Manes N, Yusa K, Moreno T, et al. Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture. Leukemia. 2013;27(9):1820–5. doi:10.1038/leu.2013.117.
Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia. 2014;28(8):1586–95. doi:10.1038/leu.2014.55.
Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220–8. doi:10.1182/blood-2013-11-537167.
Ohgami RS, Ma L, Merker JD, Gotlib JR, Schrijver I, Zehnder JL, et al. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Mod Pathol. 2015;28(5):706–14. doi:10.1038/modpathol.2014.160.
Shivarov V, Ivanova M, Naumova E. Rapid detection of DNMT3A R882 mutations in hematologic malignancies using a novel bead-based suspension assay with BNA(NC) probes. PLoS One. 2014;9(6):e99769. doi:10.1371/journal.pone.0099769.
Shivarov V, Ivanova M, Hadjiev E, Naumova E. Novel multiplex bead-based assay for detection of IDH1 and IDH2 mutations in myeloid malignancies. PLoS One. 2013;8(9):e76944. doi:10.1371/journal.pone.0076944.
Shivarov V, Ivanova M, Yaneva S, Petkova N, Hadjiev E, Naumova E. Quantitative bead-based assay for detection of JAK2 exon 12 mutations. Leuk Lymphoma. 2013;54(6):1343–4. doi:10.3109/10428194.2012.745526.
Shivarov V, Ivanova M, Hadjiev E, Naumova E. Rapid quantification of JAK2 V617F allele burden using a bead-based liquid assay with locked nucleic acid-modified oligonucleotide probes. Leuk Lymphoma. 2011;52(10):2023–6. doi:10.3109/10428194.2011.584995.
Ivanova MI, Shivarov VS, Hadjiev EA, Naumova EJ. Novel multiplex bead-based assay with LNA-modified probes for detection of MPL exon 10 mutations. Leuk Res. 2011;35(8):1120–3. doi:10.1016/j.leukres.2011.04.012.
Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012;120(15):3080–8. doi:10.1182/blood-2012-01-404863.
Kuo FC, Dong F. Next-generation sequencing-based panel testing for myeloid neoplasms. Curr Hematol Malig Rep. 2015;10(2):104–11. doi:10.1007/s11899-015-0256-3.
Black JS, Salto-Tellez M, Mills KI, Catherwood MA. The impact of next generation sequencing technologies on haematological research: a review. Pathogenesis. 2015;2(1–2):9–16. doi:10.1016/j.pathog.2015.05.004.
Kohlmann A, Nadarajah N, Alpermann T, Grossmann V, Schindela S, Dicker F, et al. Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease. Leukemia. 2014;28(1):129–37. doi:10.1038/leu.2013.239.
Gaidzik VI, Paschka P, Spath D, Habdank M, Kohne CH, Germing U, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol. 2012;30(12):1350–7. doi:10.1200/JCO.2011.39.2886.
Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264–78. doi:10.1016/j.cell.2012.06.023.
Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372(7):601–12. doi:10.1056/NEJMoa1412098.
Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 2011;118(14):3803–10. doi:10.1182/blood-2011-02-339747.
Bartels S, Schipper E, Kreipe HH, Lehmann U. Comprehensive molecular profiling of archival bone marrow trephines using a commercially available leukemia panel and semiconductor-based targeted resequencing. PLoS One. 2015;10(7):e0133930. doi:10.1371/journal.pone.0133930.
McCourt CM, McArt DG, Mills K, Catherwood MA, Maxwell P, Waugh DJ, et al. Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PLoS One. 2013;8(7):e69604. doi:10.1371/journal.pone.0069604.
Acknowledgments
We thank the Department of Hematology at Alexandrovska University Hospital for providing the clinical samples for the study.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
MI, VS, IP, KL, and EN report no conflict of interest.
Funding
MI, VS, IP, KL, and EN received no specific funding for this research.
Ethical approval and informed consent
Patients provided informed consent for molecular genetic testing and this study complied with the principles of the Declaration of Helsinki.
Rights and permissions
About this article
Cite this article
Ivanova, M., Shivarov, V., Pavlov, I. et al. Clinical Evaluation of a Novel Nine-Gene Panel for Ion Torrent PGM Sequencing of Myeloid Malignancies. Mol Diagn Ther 20, 27–32 (2016). https://doi.org/10.1007/s40291-015-0172-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40291-015-0172-1